

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM573463

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Evoform Biosciences, Inc.		04/23/2020	Corporation: DELAWARE
Evoform, Inc.		04/23/2020	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Baker Bros. Advisors LP		
Street Address:	860 Washington St., 10th Floor		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10014		
Entity Type:	Limited Partnership: DELAWARE		
PROPERTY NUMBERS Total: 6			
Property Type	Number	Word Mark	
Registration Number:	5353653	EMPOWER WOMEN CHANGE THE WORLD	
Registration Number:	5694276	EVOFORM	
Registration Number:	5619906	EVOFORM BIOSCIENCES	
Registration Number:	5638403	EVOFORM BIOSCIENCES	
Registration Number:	2026125	INSTEAD	
Registration Number:	5251161	SCIENCE WITH A SOUL	
CORRESPONDENCE DATA			
Fax Number:	9494754754		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	949-451-3800		
Email:	skann@gibsondunn.com		
Correspondent Name:	Stephanie Kann		
Address Line 1:	3161 Michelson Drive		
Address Line 2:	Gibson, Dunn & Crutcher LLP		
Address Line 4:	Irvine, CALIFORNIA 92612		
ATTORNEY DOCKET NUMBER:	12742-00010		
NAME OF SUBMITTER:	Stephanie Kann		
SIGNATURE:	/stephanie kann/		

CH \$165.00 5353653

DATE SIGNED:

04/24/2020

Total Attachments: 23

source=EVFM - Baker Bros_Evofem - IP Security Agreement#page1.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page2.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page3.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page4.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page5.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page6.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page7.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page8.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page9.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page10.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page11.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page12.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page13.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page14.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page15.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page16.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page17.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page18.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page19.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page20.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page21.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page22.tif
source=EVFM - Baker Bros_Evofem - IP Security Agreement#page23.tif

FORM OF INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of April 23, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified or replaced from time to time, this "IP Security Agreement"), is made by Evofem Biosciences, Inc., a Delaware corporation, and Evofem, Inc., a Delaware corporation (together, "Grantor"), in favor of Baker Bros. Advisors LP, a Delaware limited partnership, as collateral agent for the Purchasers (as defined in the Purchase Agreement referred to below) (in such capacity, together with its successors and permitted assigns, "Designated Agent").

WHEREAS, Grantor issued Notes (as such term is defined in the Purchase Agreement (as hereinafter defined)) pursuant to that certain Securities Purchase and Security Agreement, dated as of April 23, 2020 (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Purchase Agreement"), by and among Evofem Biosciences, Inc., a Delaware corporation (the "Company"), the Grantor and the other guarantors from time to time party thereto, the purchasers from time to time party thereto (each a "Purchaser" and collectively, the "Purchasers") and the Designated Agent, pursuant to which Grantor granted a security interest to Designated Agent, for the benefit of the Purchasers, in, among other things, the IP Collateral (as defined below) of Grantor;

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Grantor hereby agrees with Designated Agent as follows:

SECTION 1. Defined Terms

Unless otherwise defined herein, terms defined in the Purchase Agreement and used herein have the meaning given to them in the Purchase Agreement.

SECTION 2. Grant of Security Interest in IP Collateral

Grantor hereby grants to Designated Agent, for the ratable benefit of the Purchasers, a continuing security interest in all of Grantor's right, title and interest in and to the following, whether now owned or hereafter acquired, and wherever located (the "IP Collateral"), as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of Grantor's obligations under the Purchase Agreement:

(a) (i) all United States and foreign copyrights, whether or not the underlying works of authorship have been published and whether as author, assignee, transferee or otherwise, including but not limited to copyrights in software and databases, all Mask Works (as defined in 17 U.S.C. § 901 of the U.S. Copyright Act) and all works of authorship, all right, title and interest to make and exploit all derivative works based on or adopted from works covered by such copyrights, and all copyright registrations, copyright applications, mask works registrations and mask works applications, and any renewals or extensions thereof, including each registration and application identified in Schedule A, and (ii) the rights to print, publish and distribute any of the foregoing ("Copyrights");

(b) all Copyright licenses to the extent Grantor is not the granting party;

(c) (i) the right to sue or otherwise recover for any and all past, present and future infringements and misappropriations of any of the property described in (a) and (b) above, and (ii) all income, royalties, damages and other payments now and hereafter due and/or payable with respect to any of the property described in (a) and (b) above;

(d) (i) all United States, state and foreign trademarks, service marks, trade names, corporate names, company names, business names, fictitious business names, trade dress, trade styles, logos, or other indicia of origin or source identification, Internet domain names, trademark and service mark registrations, designs and general intangibles of like nature and applications for trademark or service mark registrations and any renewals thereof, including each registration and application identified in Schedule B (but excluding in all cases all intent-to-use United States trademark applications for which an amendment to allege use or statement of use has not been filed under 15 U.S.C. § 1051(c) or 15 U.S.C. § 1051(d), respectively, or if filed, has not been deemed in conformance with 15 U.S.C. § 1051(a) or examined and accepted, respectively, by the U.S. Patent and Trademark Office provided that upon such filing and acceptance, such intent-to-use applications shall be included in the definition of Trademarks) and (ii) the goodwill of the business connected with the use of, and symbolized by, each of the above (collectively, the "Trademarks");

(e) all Trademark licenses to the extent Grantor is not the granting party;

(f) (i) the right to sue or otherwise recover for any and all past, present and future infringements and misappropriations of any of the property described in (d) and (e) above, and (ii) all income, royalties, damages and other payments now and hereafter due and/or payable with respect to any of the property described in (d) and (e) above;

(g) (i) all United States and foreign patents, patent applications and patentable inventions, including each issued patent and patent application identified in Schedule C, all certificates of invention or similar property rights and all registrations, recordings and pending applications thereof, (ii) all inventions and improvements described and claimed therein and (iii) all reissues, divisions, reexaminations, continuations, continuations-in-part, substitutes, renewals, and extensions thereof, all improvements thereon (collectively, the "Patents");

(h) all Patent licenses to the extent Grantor is not the granting party;

(i) (i) the right to sue or otherwise recover for any and all past, present and future infringements and misappropriations of any of the property described in (g) and (h) above, and (ii) all income, royalties, damages and other payments now and hereafter due and/or payable with respect to any of the property described in (g) and (h) above; and

(j) all books and records relating to any of the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.

SECTION 3. Recordation

Grantor authorizes and requests that the Commissioner of Patents and Trademarks and any other applicable United States or foreign government officer record this IP Security Agreement.

SECTION 4. Execution in Counterparts

This IP Security Agreement may be executed in any number of counterparts (including by telecopy or other electronic transmission), each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

SECTION 5. Governing Law

THIS IP SECURITY AGREEMENT AND ANY CLAIM, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

SECTION 6. Conflict Provision

This IP Security Agreement has been entered into in conjunction with the provisions of the Purchase Agreement. The rights and remedies of each party hereto with respect to the security interest granted herein are without prejudice to, and are in addition to those set forth in the Purchase Agreement, all terms and provisions of which are incorporated herein by reference. In the event that any provisions of this IP Security Agreement are in conflict with the Purchase Agreement, the provisions of the Purchase Agreement, as applicable, shall govern.

[Signature pages follow]

IN WITNESS WHEREOF, each of the undersigned has caused this IP Security Agreement to be duly executed and delivered as of the date first above written.

GRANTOR:

EVOFEM BIOSCIENCES, INC.
a Delaware corporation

By: *Sandra Pelletier*
Name: Sandra Pelletier
Title: President and Chief Executive Officer

IN WITNESS WHEREOF, each of the undersigned has caused this IP Security Agreement to be duly executed and delivered as of the date first above written.

GRANTOR:
EVOFEM, INC.
a Delaware corporation


By: *Saundra Pelletier*
Name: Saundra Pelletier
Title: President and Chief Executive Officer

[Signature Page to IP Security Agreement]

TRADEMARK
REEL: 006922 FRAME: 0955

DESIGNATED AGENT:

BAKER BROS. ADVISORS LP,
a Delaware limited partnership

By: 
Name: Scott Lessing
Title:

Schedule A
COPYRIGHTS

None.

Schedule B
TRADEMARKS

See attached.

PH EXXI	Australia	NA	054498-408T01AU	Registered	Evofem Biosciences, Inc.	2007203	May 3, 2019	2007203	Oct 28, 2019	Feb 3, 2029	05	microbical that creates an inhospitable environment for spermatozoa; microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
MVP-R	European Union	NA	054498-408T01EM	Registered	Evofem Biosciences, Inc.	018060177	May 3, 2019	018060177	Sep 27, 2019	Feb 3, 2029	05	05: Personal lubricant, personal sexual lubricants, microbical that creates an inhospitable environment for spermatozoa; microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PH EXXI	Australia	NA	054498-412T01AU	Pending	Evofem Biosciences, Inc.	2064040	Jan 22, 2020				05	05: Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PH EXXI	Brazil	NA	054498-412T01BR	Pending	Evofem Biosciences, Inc.	919143915	Feb 3, 2020				05	05: Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbical that creates an inhospitable environment for spermatozoa; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PH EXXI	Canada	NA	054498-412T01CA	Pending	Evofem Biosciences, Inc.	1,982,592	Aug 28, 2019				05	05: Pharmaceutical preparations for vaginal lubrication; vaginal microbical spermicidal gel; personal lubricant; personal sexual lubricants; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for spermatozoa; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PH EXXI	Switzerland	NA	054498-412T01CH	Pending	Evofem Biosciences, Inc.	008142030	Jan 22, 2020				05	05: Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbical that creates an inhospitable environment for spermatozoa; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PH EXXI	Chile	NA	054498-412T01CL	Pending	Evofem Biosciences, Inc.	1349132	Feb 14, 2020				05	05: Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbical that creates an inhospitable environment for spermatozoa; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PH EXXI	China	NA	054498-412T01CN	Pending	Evofem Biosciences, Inc.	TBD	Feb 10, 2020				05	05: Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbical that creates an inhospitable environment for spermatozoa; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PH EXXI	Hong Kong	NA	054498-412T01HK	Pending	Evofem Biosciences, Inc.	305178051	Jan 22, 2020				05	05: Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbical that creates an inhospitable environment for spermatozoa; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.

PH EXXI	Israel	NA	054498-412701IL	Pending	Evofem Biosciences, Inc.	330523	Sep 16, 2019	05	05-Pharmaceutical preparations for vaginal lubrication; vaginal (microbical) spermicidal gel; personal lubricant; personal sexual lubricants; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for spermatozoa;
PH EXXI	India	NA	054498-412701IN	Pending	Evofem Biosciences, Inc.	4416324	Jan 22, 2020	05	05-Pharmaceutical preparations, namely, microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for spermatozoa; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optional environment;
PH EXXI	Japan	NA	054498-412701JP	Pending	Evofem Biosciences, Inc.	2020-66882	Jan 22, 2020	05	05-Personal lubricant; personal sexual lubricants; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for spermatozoa; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optional environment;
PH EXXI	Kenya	NA	054498-412701KE	Pending	Evofem Biosciences, Inc.	110732	Jan 24, 2020	05	05-Personal lubricant; personal sexual lubricants; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for spermatozoa; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optional environment;
PH EXXI	Cambodia	NA	054498-412701KH	Pending	Evofem Biosciences, Inc.	KH/7/2020/90546	Feb 6, 2020	05	05-Personal lubricant; personal sexual lubricants; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for spermatozoa; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optional environment;
PH EXXI	Republic of Korea	NA	054498-412701KR	Pending	Evofem Biosciences, Inc.	40-2020-0013995	Jan 29, 2020	05	05-Personal lubricant; personal sexual lubricants; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for spermatozoa; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optional environment;
PH EXXI	Laos	NA	054498-412701LA	Pending	Evofem Biosciences, Inc.	44213	Jan 24, 2020	05	05-Personal lubricant; personal sexual lubricants; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for spermatozoa; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optional environment;
PH EXXI	Mexico	NA	054498-412701MX	Pending	Evofem Biosciences, Inc.	2318871	Jan 21, 2020	05	05-Personal lubricant; personal sexual lubricants; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for spermatozoa; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optional environment;
PH EXXI	Malaysia	NA	054498-412701MY	Pending	Evofem Biosciences, Inc.	TM/2020/001388	Jan 22, 2020	05	05-Personal lubricant; personal sexual lubricants; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for spermatozoa; pharmaceutical preparations, namely, microbical that creates an inhospitable environment for viral and bacterial pathogens; pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optional environment;

PHEXXI	Nigeria	NA	054498-412T01NG	Pending	Evofem Biosciences, Inc.	F/TM/O/2020/166726	Jan 24, 2020	05	05 Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for spermatozoa, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for viral and bacterial pathogens, pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PHEXXI	Norway	NA	054498-412T01NO	Pending	Evofem Biosciences, Inc.	2020010211	Jan 22, 2020	05	05 Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for spermatozoa, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for viral and bacterial pathogens, pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PHEXXI	Philippines	NA	054498-412T01PH	Pending	Evofem Biosciences, Inc.	4-2020-002021	Feb 6, 2020	05	05 Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for spermatozoa, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for viral and bacterial pathogens, pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PHEXXI	Russian Federation	NA	054498-412T01RU	Pending	Evofem Biosciences, Inc.	202002220	Jan 22, 2020	05	05 Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for spermatozoa, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for viral and bacterial pathogens, pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PHEXXI	Singapore	NA	054498-412T01SG	Pending	Evofem Biosciences, Inc.	40202001442P	Jan 22, 2020	05	05 Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for spermatozoa, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for viral and bacterial pathogens, pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PHEXXI	Thailand	NA	054498-412T01TH	Pending	Evofem Biosciences, Inc.	202003118	Jan 24, 2020	05	05 Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for spermatozoa, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for viral and bacterial pathogens, pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PHEXXI	Turkey	NA	054498-412T01TR	Pending	Evofem Biosciences, Inc.	2020/14476	Feb 5, 2020	05	05 Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for spermatozoa, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for viral and bacterial pathogens, pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PHEXXI	Vietnam	NA	054498-412T01VM	Pending	Evofem Biosciences, Inc.	4-2020-02792	Jan 22, 2020	05	05 Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for spermatozoa, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for viral and bacterial pathogens, pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PHEXXI	South Africa	NA	054498-412T01ZA	Pending	Evofem Biosciences, Inc.	2020/01526	Jan 22, 2020	05	05 Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for spermatozoa, pharmaceutical preparations, namely, microbiodical that creates an inhospitable environment for viral and bacterial pathogens, pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.

PHEXI	European Union	NA	054498-412T01EM	Published	Evoform Biosciences, Inc.	038199548	Jan 30, 2020	05	05: Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbicides that creates an inhospitable environment for spermatozoa, pharmaceutical preparations, namely, microbicides that creates an inhospitable environment for viral and bacterial pathogens, pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PHEXI	Indonesia	NA	054498-412T01ID	Published	Evoform Biosciences, Inc.	DD202000429 5	Jan 24, 2020	05	05: Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbicide that creates an inhospitable environment for spermatozoa, pharmaceutical preparations, namely, microbicide that creates an inhospitable environment for viral and bacterial pathogens, pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
PHEXI	New Zealand	NA	054498-412T01NZ	Published	Evoform Biosciences, Inc.	1139134	Jan 22, 2020	05	05: Personal lubricant, personal sexual lubricants, pharmaceutical preparations, namely, microbicides that creates an inhospitable environment for spermatozoa, pharmaceutical preparations, namely, microbicides that creates an inhospitable environment for viral and bacterial pathogens, pharmaceutical acid buffering gel with bio adhesive properties designed to maintain an optimal environment.
SCIENCE WITH A SOUL	United States of America	Principal	054498-405T01US	Registered	Evoform Biosciences, Inc.	87/290,846	Jan 5, 2017	42	42: Research and development of medical, pharmaceutical, therapeutic and technological solutions for women's healthcare.

Schedule C
PATENTS

See attached.

EVOFEM U.S./PCT PATENT LIST

APPLICATION NUMBER	PATENT NUMBER	TITLE
14/410,841		COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
14/864,673	9,566,232	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
15/106,755		COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
15/410,632		COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
16/239,314	10,568,855	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
16/332,290		COMBINATION GEL FOR SEXUALLY TRANSMITTED INFECTIONS
16/338,977		METHOD OF TREATMENT AND PREVENTION OF BACTERIAL VAGINOSIS
16/738,868		COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
61/659,368		COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF MICROBICIDES
61/901,306		METHODS FOR MANUFACTURING CONTRACEPTIVE MICROBICIDES WITH ANTIVIRAL PROPERTIES
61/918,445		COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
62/393,578		COMBINATION GEL FOR SEXUALLY TRANSMITTED INFECTIONS
62/404,061		METHOD OF TREATMENT AND PREVENTION OF BACTERIAL VAGINOSIS
PCT/US13/32510		COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
PCT/US14/64639		METHODS FOR MANUFACTURING CONTRACEPTIVE MICROBICIDES WITH ANTIVIRAL PROPERTIES

PCT/US14/71664		COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
PCT/US17/50960		COMBINATION GEL FOR SEXUALLY TRANSMITTED INFECTIONS
PCT/US17/54943		METHOD OF TREATMENT AND PREVENTION OF BACTERIAL VAGINOSIS

EVOFEM FOREIGN PATENT LIST

APPLICATION NUMBER	PATENT NUMBER	STATUS	COUNTRY NAME	TITLE
1201400533	17704	Issued	African Intellectual Property Organization (OAPI)	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
AP/P/2014/008149	AP 4100	Issued	ARIPO	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
2017206199	2017206199	Issued	Australia	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
2013274815	2013274815	Issued	Australia	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
2014368971		Pending	Australia	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
2017338748		Pending	Australia	METHOD OF TREATMENT AND PREVENTION OF BACTERIAL VAGINOSIS
14871611.1	3082826	Issued	Belgium	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
BR112014030984.1		Pending	Brazil	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
1120160145062		Pending	Brazil	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND

201910881646.8		Pending	China	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
201380030151.5		Abandoned	China	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
201480075975.9		Pending	China	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
201780070201.0		Pending	China	METHOD OF TREATMENT AND PREVENTION OF BACTERIAL VAGINOSIS
14871611.1	3082826	Issued	Denmark	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
201590008		Pending	Eurasian Patent Office	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
17200193.5		Pending	European Patent Office	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
13804259.3		Pending	European Patent Office	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
20161479.9		Pending	European Patent Office	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
14871611.1	3082826	Issued	European Patent Office	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
17859019.6		Pending	European Patent Office	METHOD OF TREATMENT AND PREVENTION OF BACTERIAL VAGINOSIS

14871611.1	3082826	Issued	Finland	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
14871611.1	3082826	Issued	France	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
14871611.1	3082826	Issued	Germany	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
15109540.9		Abandoned	Hong Kong	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
17104104.6		Pending	Hong Kong	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
62020002675.0		Pending	Hong Kong	METHOD OF TREATMENT AND PREVENTION OF BACTERIAL VAGINOSIS
237/CHENP/2015	329736	Issued	India	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
201617024662		Pending	India	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
P00201500023	P00201500023	Issued	Indonesia	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
14871611.1	3082826	Issued	Ireland	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND

235812		Pending	Israel	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
246146		Pending	Israel	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
14871611.1	3082826	Issued	Italy	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
2018-026423		Pending	Japan	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
2015-517245	6352907	Issued	Japan	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
2020-063444		Pending	Japan	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
2016-560871		Abandoned	Japan	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
2019-538583		Pending	Japan	METHOD OF TREATMENT AND PREVENTION OF BACTERIAL VAGINOSIS
14871611.1	3082826	Issued	Luxembourg	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
MX/A/2019/007176		Pending	Mexico	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES

MX/A/2014/015307	365905	Issued	Mexico	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
MX/a/2016/008023		Pending	Mexico	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
14871611.1	3082826	Issued	Netherlands	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
703203	703203	Issued	New Zealand	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
722215	722215	Issued	New Zealand	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
14871611.1	3082826	Issued	Norway	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
10-2015-7000465	10-2062599	Issued	Republic of Korea	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES
10-2016-7019494		Pending	Republic of Korea	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
2019116087		Pending	Russian Federation	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
2016129069	2691950	Issued	Russian Federation	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES

					USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND
11201408243V	11201408243V	Issued	Singapore	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES	
2015/00111	2015/00111	Issued	South Africa	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES	
2016/04862	2016/04862	Issued	South Africa	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND	
14871611.1	3082826	Issued	Spain	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND	
14871611.1	3082826	Issued	Sweden	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND	
14871611.1	3082826	Issued	Switzerland	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND	
1401007416		Pending	Thailand	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES	
a 2015 00194	0115876	Issued	Ukraine	COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES	
14871611.1	3082826	Issued	United Kingdom	COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND	
1-2015-00086		Allowed	Vietnam	A Contraceptive Microbicide Composition	

